User contributions for Gloria Picoy
Jump to navigation
Jump to search
10 February 2015
- 17:2617:26, 10 February 2015 diff hist 0 N File:Oritavancin Outcomes by Baseline Pathogen.png No edit summary current
- 17:2517:25, 10 February 2015 diff hist 0 N File:Oritavancin Clinical Success Rates in ABSSSI Trials at the Follow-Up Visit.png No edit summary current
- 17:2317:23, 10 February 2015 diff hist 0 N File:Oritavancin Clinical Response Rates in ABSSSI Trials using Reduction in Lesion Area of 20% or Greater at 48-72 Hours after Initiation of Therapy.png No edit summary current
- 17:2117:21, 10 February 2015 diff hist 0 N File:Oritavancin Clinical Response Rates in ABSSSI Trials using Responders at 48-72 Hours after Initiation of Therapy.png No edit summary current
- 17:1417:14, 10 February 2015 diff hist 0 N File:Oritavancin Chemical structure.png No edit summary current
- 17:0717:07, 10 February 2015 diff hist 0 N File:Oritavancin Population Mean Plasma Concentration.png No edit summary current
- 17:0517:05, 10 February 2015 diff hist 0 N File:Oritavancin Mean PK parameters.png No edit summary current
- 17:0017:00, 10 February 2015 diff hist 0 N File:Oritavancin Adverse reactions.png No edit summary current
9 February 2015
- 19:3019:30, 9 February 2015 diff hist +10,763 Oritavancin No edit summary
- 19:1319:13, 9 February 2015 diff hist +31 Long QT Syndrome differential diagnosis →Causes in Alphabetical Order current
- 19:1319:13, 9 February 2015 diff hist +30 Anaphylaxis causes →Causes in Alphabetical Order
- 19:1319:13, 9 February 2015 diff hist +31 Proteinuria →Causes in Alphabetical Order
- 19:1219:12, 9 February 2015 diff hist +31 Nausea and vomiting causes →Causes in Alphabetical Order
- 19:1219:12, 9 February 2015 diff hist +13 Dysgeusia →Causes in Alphabetical Order
- 19:1119:11, 9 February 2015 diff hist −1 Proteinuria →Causes by Organ System
- 19:1119:11, 9 February 2015 diff hist +30 Long QT Syndrome differential diagnosis →Causes by Organ System
- 19:1119:11, 9 February 2015 diff hist +30 Acute kidney injury →Drug Side Effect
- 19:1019:10, 9 February 2015 diff hist +30 Anaphylaxis causes →Causes by Organ System
- 19:1019:10, 9 February 2015 diff hist +30 Proteinuria →Causes by Organ System
- 19:1019:10, 9 February 2015 diff hist +30 Nausea and vomiting causes →Causes by Organ System
- 19:0919:09, 9 February 2015 diff hist +14 Dysgeusia →Causes by Organ System
- 19:0719:07, 9 February 2015 diff hist +72 Telavancin hydrochloride No edit summary current
- 19:0019:00, 9 February 2015 diff hist +8 Telavancin hydrochloride No edit summary
- 18:5618:56, 9 February 2015 diff hist −2,827 Telavancin #REDIRECT __NOTOC__ current
- 18:5618:56, 9 February 2015 diff hist +38 N Vibativ #REDIRECT current
- 18:5318:53, 9 February 2015 diff hist +3,196 Telavancin hydrochloride No edit summary
- 18:5218:52, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride structure.png No edit summary current
- 18:5018:50, 9 February 2015 diff hist +17 Telavancin hydrochloride No edit summary
- 17:3617:36, 9 February 2015 diff hist +2,143 Telavancin hydrochloride No edit summary
- 17:3517:35, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride 250 mg.png No edit summary current
- 17:3517:35, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride 750 mg.png No edit summary current
- 17:3117:31, 9 February 2015 diff hist +5,626 Telavancin hydrochloride No edit summary
- 17:3017:30, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Clinical Response Rates in Trials 1 and 2 – AT and CE Populations.png No edit summary current
- 17:2917:29, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride All-Cause Mortality at Day 28 in Patients with at least One Baseline Gram-Positive Pathogen.png No edit summary current
- 17:2617:26, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Clinical Cure Rates at the Test-of-Cure for the Most Common Pathogens in cSSSI Trials 1 and 2.png No edit summary current
- 17:2517:25, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Clinical Cure at Test-of-Cure in cSSSI Trials 1 and 2.png No edit summary current
- 17:2417:24, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Baseline Infection Types in Patients in cSSSI.png No edit summary current
- 17:2117:21, 9 February 2015 diff hist +17,907 Telavancin hydrochloride No edit summary
- 17:1917:19, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride pharmacokinetics.png No edit summary current
- 17:1717:17, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride pharmacodynamics.png No edit summary current
- 17:1417:14, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride HABP-VABP adverse reactions.png No edit summary current
- 17:1217:12, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride HABP-VABP.png No edit summary current
- 17:1017:10, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Complicated Skin and Skin Structure Infections.png No edit summary current
- 17:0617:06, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Coagulation Tests Affected and Unaffected by Telavancin.png No edit summary current
- 17:0417:04, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride Decreased Clinical Response in Patients with cSSSI and Pre-existing Renal Impairment.png No edit summary current
- 17:0117:01, 9 February 2015 diff hist +18,397 N Telavancin hydrochloride Created page with "{{DrugProjectFormSinglePage |authorTag={{GP}} |genericName=Telavancin hydrochloride |aOrAn=an |drugClass=antibiotic |indicationType=treatment |indication=Complicated skin and..."
- 17:0117:01, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride FDA package label.png No edit summary current
- 16:4616:46, 9 February 2015 diff hist 0 N File:Telavancin hydrochloride chemical structure.png No edit summary current
- 16:2716:27, 9 February 2015 diff hist −10 Pyrantel pamoate No edit summary current
- 16:2716:27, 9 February 2015 diff hist +30 Pyrantel ←Redirected page to Pyrantel pamoate current